Published: May 24, 2023 at 4:50 p.m. ET
Health-care companies fell, but not by as much as the broad market, as investors held out hope for a debt-ceiling compromise.
“Polls have moved from ‘it’s all Biden’s fault’ to its ‘Biden and your guys’ fault,'” said Oliver Pursche, senior vice president at financial advisory Wealthspire.
“And that’s a big difference…going into this election…
Health-care companies fell, but not by as much as the broad market, as investors held out hope for a debt-ceiling compromise.
“Polls have moved from ‘it’s all Biden’s fault’ to its ‘Biden and your guys’ fault,'” said Oliver Pursche, senior vice president at financial advisory Wealthspire.
“And that’s a big difference…going into this election cycle. That makes me think, there’s motivation to come to a deal and negotiate is there on both sides,” said Pursche.
Sarepta Therapeutics shares fell sharply after the biotech concern disclosed that the Food and Drug Administration had delayed its decision date on a muscular-dystrophy gene therapy developed by Sarepta.
Write to Rob Curran at rob.curran@dowjones.com
[ad_2]
Comments